Pharmacokinetics of gacyclidine enantiomers in plasma and spinal cord after single enantiomer administration in rats.
The purpose of this study was to determine the pharmacokinetics of gacyclidine, a non-competitive NMDA antagonist, in plasma and spinal cord extracellular fluid (ECF) after IV administration of single enantiomers in rats. After implantation of microdialysis probes in spinal cord, concentrations in plasma and ECF dialysates were determined by a chiral GC/MS assay over 5 h after administration of either (+)-gacyclidine or (-)-gacyclidine (1.25 mg/kg). Plasma protein binding was estimated in vitro by equilibrium dialysis. Plasma concentrations decayed in parallel in a biphasic manner (t(1/2)alpha approximately 9 min; t(1/2)beta approximately 90 min) with no significant difference between the two enantiomers. Clearance of (+)-gacyclidine and (-)-gacyclidine (291 versus 275 ml/min per kg, respectively), volume of distribution (Vdbeta: 38 versus 40 l/kg), and protein binding (90 versus 89%) were not stereoselective. Both gacyclidine enantiomers were quantifiable in spinal cord ECF 10 min after drug administration and their concentrations remained stable over the duration of the experiment in spite of changing blood concentrations. Penetration of the two enantiomers in spinal cord ECF was similar although highly variable between animals. Exposure of spinal cord ECF was comparable for both enantiomers, and not correlated with plasma AUCs. This study showed the absence of any pharmacokinetic difference between the two enantiomers when administered individually, and no enantiomeric inversion. Both gacyclidine enantiomers penetrate rapidly and extensively into spinal cord ECF, and their distribution may involve an active transport system.
Hoizey
G
G
Laboratoire de Pharmacologie et de Pharmacocinétique, U.F.R. de Pharmacie, Université de Reims Champagne-Ardenne, 51, rue Cognacq-Jay 51096, Cedex, Reims, France. ghoizey@aol.com
Kaltenbach
M L
ML
Dukic
S
S
Lamiable
D
D
Millart
H
H
D'Arbigny
P
P
Vistelle
R
R
D000818:Animals; D001798:Blood Proteins / Q000378:metabolism; D002138:Calibration; D003510:Cyclohexanes / Q000737:chemistry / Q000493:pharmacokinetics*; D053138:Cyclohexenes; D018691:Excitatory Amino Acid Antagonists / Q000737:chemistry / Q000493:pharmacokinetics*; D005110:Extracellular Space / Q000378:metabolism; D006207:Half-Life; D007275:Injections, Intravenous; D008297:Male; D017551:Microdialysis; D010880:Piperidines / Q000737:chemistry / Q000493:pharmacokinetics*; D051381:Rats; D017208:Rats, Wistar; D016194:Receptors, N-Methyl-D-Aspartate / Q000037:antagonists & inhibitors*; D013116:Spinal Cord / Q000378:metabolism*; D013237:Stereoisomerism
D001798:Blood Proteins; D003510:Cyclohexanes; D053138:Cyclohexenes; D018691:Excitatory Amino Acid Antagonists; D010880:Piperidines; D016194:Receptors, N-Methyl-D-Aspartate; C070707:gacyclidine